Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.

PubWeight™: 1.95‹?› | Rank: Top 2%

🔗 View Article (PMC 133469)

Published in EMBO J on February 01, 2001

Authors

C Wong1, L W Xiong, M Horiuchi, L Raymond, K Wehrly, B Chesebro, B Caughey

Author Affiliations

1: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories/NIH, 903 South 4th Street, Hamilton, MT 59840, USA.

Articles citing this

Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A (2007) 5.94

Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem (2009) 2.80

Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. EMBO J (2002) 2.16

Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol (2004) 1.97

Selective incorporation of polyanionic molecules into hamster prions. J Biol Chem (2007) 1.71

Strains of [PSI(+)] are distinguished by their efficiencies of prion-mediated conformational conversion. EMBO J (2001) 1.70

Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry (2010) 1.68

Production of cattle lacking prion protein. Nat Biotechnol (2006) 1.63

Synthetic prions generated in vitro are similar to a newly identified subpopulation of PrPSc from sporadic Creutzfeldt-Jakob Disease. Protein Sci (2005) 1.62

Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog (2010) 1.49

Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein. Protein Eng Des Sel (2009) 1.49

The expanding universe of prion diseases. PLoS Pathog (2006) 1.45

Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol (2007) 1.42

Prion protein glycosylation is not required for strain-specific neurotropism. J Virol (2009) 1.31

Cell-surface prion protein interacts with glycosaminoglycans. Biochem J (2002) 1.27

In vitro detection of prionemia in TSE-infected cervids and hamsters. PLoS One (2013) 1.17

Prion strain-dependent differences in conversion of mutant prion proteins in cell culture. J Virol (2006) 1.14

Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother (2006) 1.08

Cellular factors implicated in prion replication. FEBS Lett (2010) 1.07

Sulfated dextrans enhance in vitro amplification of bovine spongiform encephalopathy PrP(Sc) and enable ultrasensitive detection of bovine PrP(Sc). PLoS One (2010) 1.05

Glypican-1 mediates both prion protein lipid raft association and disease isoform formation. PLoS Pathog (2009) 1.04

Recent advances in prion chemotherapeutics. Infect Disord Drug Targets (2009) 1.03

Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans. Proc Natl Acad Sci U S A (2007) 1.02

The role of cofactors in prion propagation and infectivity. PLoS Pathog (2012) 0.99

In situ photodegradation of incorporated polyanion does not alter prion infectivity. PLoS Pathog (2011) 0.97

Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway. J Biol Chem (2009) 0.96

Cellular aspects of prion replication in vitro. Viruses (2013) 0.95

Charge neutralization of the central lysine cluster in prion protein (PrP) promotes PrP(Sc)-like folding of recombinant PrP amyloids. J Biol Chem (2014) 0.94

The role of the 132-160 region in prion protein conformational transitions. Protein Sci (2005) 0.94

Low density subcellular fractions enhance disease-specific prion protein misfolding. J Biol Chem (2010) 0.94

Redox control of prion and disease pathogenesis. Antioxid Redox Signal (2010) 0.93

Synthesis of high titer infectious prions with cofactor molecules. J Biol Chem (2014) 0.92

Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan. J Mol Biol (2009) 0.91

Structural requirements for efficient prion protein conversion: cofactors may promote a conversion-competent structure for PrP(C). Prion (2010) 0.86

Glycosylphosphatidylinositol anchor-dependent stimulation pathway required for generation of baculovirus-derived recombinant scrapie prion protein. J Virol (2011) 0.85

Heparin binding confers prion stability and impairs its aggregation. FASEB J (2014) 0.85

Unusual cerebral vascular prion protein amyloid distribution in scrapie-infected transgenic mice expressing anchorless prion protein. Acta Neuropathol Commun (2013) 0.85

Rapid oligomer formation of human muscle acylphosphatase induced by heparan sulfate. Nat Struct Mol Biol (2012) 0.83

Lipopolysaccharide induced conversion of recombinant prion protein. Prion (2014) 0.83

Prion propagation in vitro: are we there yet? Int J Med Sci (2008) 0.82

Prion protein misfolding, strains, and neurotoxicity: an update from studies on Mammalian prions. Int J Cell Biol (2013) 0.82

Glycosaminoglycan sulphation affects the seeded misfolding of a mutant prion protein. PLoS One (2010) 0.82

Ligand binding promotes prion protein aggregation--role of the octapeptide repeats. FEBS J (2008) 0.82

Prion protein misfolding. Curr Mol Med (2009) 0.82

Plasminogen: A cellular protein cofactor for PrPSc propagation. Prion (2011) 0.81

Heparin induces harmless fibril formation in amyloidogenic W7FW14F apomyoglobin and amyloid aggregation in wild-type protein in vitro. PLoS One (2011) 0.80

Binding of recombinant but not endogenous prion protein to DNA causes DNA internalization and expression in mammalian cells. J Biol Chem (2008) 0.80

Prion propagation and toxicity occur in vitro with two-phase kinetics specific to strain and neuronal type. J Virol (2012) 0.80

Insect cell-derived cofactors become fully functional after proteinase K and heat treatment for high-fidelity amplification of glycosylphosphatidylinositol-anchored recombinant scrapie and BSE prion proteins. PLoS One (2013) 0.79

A specific population of abnormal prion protein aggregates is preferentially taken up by cells and disaggregated in a strain-dependent manner. J Virol (2013) 0.79

A computational approach for identifying the chemical factors involved in the glycosaminoglycans-mediated acceleration of amyloid fibril formation. PLoS One (2010) 0.79

Early Generation of New PrPSc on Blood Vessels after Brain Microinjection of Scrapie in Mice. MBio (2015) 0.79

Photodegradation illuminates the role of polyanions in prion infectivity. Prion (2011) 0.78

Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake. J Virol (2015) 0.78

Molecular interactions between prions as seeds and recombinant prion proteins as substrates resemble the biological interspecies barrier in vitro. PLoS One (2010) 0.78

Glycoform-independent prion conversion by highly efficient, cell-based, protein misfolding cyclic amplification. Sci Rep (2016) 0.78

Role of lipid in forming an infectious prion? Acta Biochim Biophys Sin (Shanghai) (2013) 0.78

Prion protein self-peptides modulate prion interactions and conversion. BMC Biochem (2009) 0.76

PrP knockout cells expressing transmembrane PrP resist prion infection. J Virol (2016) 0.76

In vitro amplification of scrapie and chronic wasting disease PrP(res) using baculovirus-expressed recombinant PrP as substrate. Prion (2014) 0.75

Heparan Sulfate and Heparin Promote Faithful Prion Replication in Vitro by Binding to Normal and Abnormal Prion Proteins in Protein Misfolding Cyclic Amplification. J Biol Chem (2016) 0.75

Articles cited by this

Novel proteinaceous infectious particles cause scrapie. Science (1982) 24.09

Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A (1993) 10.36

Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med (1998) 9.01

Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol (1987) 7.05

NMR structure of the mouse prion protein domain PrP(121-231). Nature (1996) 6.37

Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell (1990) 6.17

Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07

Self-replication and scrapie. Nature (1967) 6.01

Purification and structural studies of a major scrapie prion protein. Cell (1984) 5.98

Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry (1991) 5.53

Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell (1995) 5.16

Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell (1987) 5.12

The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem (1991) 4.23

Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature (1995) 4.22

Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. Proc Natl Acad Sci U S A (1997) 4.10

NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett (1997) 3.90

N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J Virol (1991) 3.55

Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci U S A (1997) 3.42

Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol (1993) 3.07

Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80

Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc Natl Acad Sci U S A (1994) 2.70

The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice. J Gen Virol (1989) 2.64

Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58

Species-barrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci U S A (2000) 2.50

Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J (2000) 2.42

Evidence that the transmission of one source of scrapie agent to hamsters involves separation of agent strains from a mixture. J Gen Virol (1978) 2.33

Scrapie infectivity found in resistant species. Nature (1998) 2.28

Temporary and permanent modifications to a single strain of mouse scrapie on transmission to rats and hamsters. J Gen Virol (1987) 2.27

A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87

Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol (1984) 1.87

Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85

pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231). J Biol Chem (1997) 1.85

Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected]. J Virol (1994) 1.85

Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79

Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A (2000) 1.73

Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol (1986) 1.66

Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J (1999) 1.64

Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc Natl Acad Sci U S A (1999) 1.60

Cell-surface engineering with GPI-anchored proteins. FASEB J (1996) 1.59

Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother (1986) 1.56

Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55

Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms. Proc Natl Acad Sci U S A (1997) 1.54

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem (1995) 1.51

BSE and prions: uncertainties about the agent. Science (1998) 1.50

Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J Virol (1997) 1.38

Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. Lab Invest (1990) 1.32

Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol (1989) 1.26

Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol (1993) 1.26

Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging (1989) 1.19

Characterization and polyanion-binding properties of purified recombinant prion protein. Biochem J (1999) 0.97

Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J Virol (2000) 0.97

Scrapie associated PrP accumulation and its prevention: insights from cell culture. Br Med Bull (1993) 0.97

Prion rods contain an inert polysaccharide scaffold. Biol Chem (1999) 0.95

Assays of protease-resistant prion protein and its formation. Methods Enzymol (1999) 0.89

Scrapie-associated PrP accumulation and agent replication: effects of sulphated glycosaminoglycan analogues. Philos Trans R Soc Lond B Biol Sci (1994) 0.83

Articles by these authors

Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94

Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76

Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol (1992) 6.72

Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07

Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51

Relative survival and the estimation of net survival: elements for further discussion. Stat Med (1990) 4.41

TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41

Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26

Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature (1995) 4.22

Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16

ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci (2001) 3.72

Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61

Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ (1994) 3.45

Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44

Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38

Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21

Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89

Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol (1990) 2.88

Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80

Use of a focal immunofluorescence assay on live cells for quantitation of retroviruses: distinction of host range classes in virus mixtures and biological cloning of dual-tropic murine leukemia viruses. Virology (1985) 2.74

Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69

p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65

Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58

Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55

Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54

Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet (1995) 2.52

Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51

Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44

Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J (2000) 2.42

Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39

Scrapie infectivity found in resistant species. Nature (1998) 2.28

Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28

Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21

Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol (2000) 2.15

Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08

T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06

Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01

Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95

Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95

Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol (1996) 1.94

Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93

Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol (1988) 1.92

Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92

Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90

A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87

Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem (1993) 1.87

A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells. Proc Natl Acad Sci U S A (1996) 1.87

Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85

Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients. J Infect Dis (1991) 1.85

Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. J Virol (2001) 1.84

The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A (1995) 1.82

Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A (1998) 1.80

Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79

Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79

The chemistry of scrapie infection: implications of the 'ice 9' metaphor. Chem Biol (1995) 1.76

Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes (1999) 1.74

Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A (2000) 1.73

[A case control study for the evaluation of the cytological detection of cancer of the cervix]. Rev Epidemiol Sante Publique (1984) 1.72

A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A (1995) 1.71

Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71

Strains of [PSI(+)] are distinguished by their efficiencies of prion-mediated conformational conversion. EMBO J (2001) 1.70

Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer (1988) 1.69

Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69

Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68

Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J Immunol (1978) 1.66

The ultrastructure of normal and pathological IgM immunoglobulins. J Exp Med (1968) 1.64

Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J (1999) 1.64

Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production. J Exp Med (1979) 1.63

Effect of murine host genotype on MCF virus expression, latency, and leukemia cell type of leukemias induced by Friend murine leukemia helper virus. Virology (1983) 1.62

Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A (1996) 1.61

Amino acid polymorphisms of PrP with reference to onset of scrapie in Suffolk and Corriedale sheep in Japan. J Gen Virol (1995) 1.61

Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res (1991) 1.61

Role of the host immune response in selection of equine infectious anemia virus variants. J Virol (1987) 1.56